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Abstract The receptor for epidermal growth factor (EGFR,
ErbB1, HER1) supports the growth and maintenance of a
broad range of human tumor types, and EGFR-targeting
drugs are approved for the treatment of several advanced
stage cancers, including non-small cell lung cancer
(NSCLC), pancreatic cancer, squamous cell cancer of the
head and neck (SCCHN), and colorectal cancer. Recent
years have witnessed significant advances in our under-
standing of dysregulated signal transduction in cancer cells
resulting from changes in the expression and/or mutational
status of key signaling molecules that modulate sensitivity
to drugs targeting EGFR. Based on this knowledge, we
have an exciting opportunity to maximize the benefit
provided to cancer patients by EGFR inhibitors. In this
review article, we describe molecular determinants of
sensitivity or resistance to EGFR-targeted agents, with
specific emphasis on EGFR tyrosine kinase inhibitors
(TKIs). The impact of these findings on our ability to
evaluate candidate predictive biomarkers and to design
robust mechanism-based combination strategies is also
discussed.
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Introduction
The receptor for epidermal growth factor (EGFR, ErbB1,
HER1) is overexpressed in a broad range of human cancers,
including non-small cell lung cancer (NSCLC), pancreatic
cancer, squamous cell cancer of the head and neck
(SCCHN), as well as colorectal, breast, hepatocellular and
ovarian carcinomas [1–6]. EGFR signaling contributes to
the growth and survival of tumor cells through its ability to
activate multiple signal transduction networks including the
mitogen-activated protein kinase (MAPK) and AKT path-
ways. In preclinical models, inhibition of EGFR signaling
either by antibodies that neutralize ligand-mediated activa-
tion or small molecule kinase inhibitors results in decreased
tumor cell proliferation and/or viability in vitro and
inhibition of tumor growth in vivo. Anti-EGFR monoclonal
antibodies (e.g., cetuximab, panitumumab) have been
approved for the treatment of advanced SCCHN and
colorectal cancer [7–9] and EGFR tyrosine kinase inhibitors
(TKI) (e.g., erlotinib, gefitinib) have been approved for the
treatment of advanced NSCLC and pancreatic cancer [10–
14]. The approval of these drugs has been based on
demonstration of modest efficacy in large clinical studies
that enrolled broad patient populations and it is clear that
relatively small proportions of patients received dramatic
benefit whereas the majority of patients received little to no
benefit. These observations highlight the need for bio-
markers that will identify those patients most likely to
maximally benefit from EGFR-targeted drugs as mono-
therapies or in combination with other anticancer agents.
This review article will focus on recent advances in our
understanding of tumor cell signaling that mediates sensi-
tivity or resistance to EGFR TKIs and how this knowledge
has led to the identification of potential biomarkers that
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might be used to identify patients most likely to benefit
from treatment with EGFR TKIs.
EGFR signaling and ErbB3
An understanding of the signal transduction pathways that
mediate sensitivity to EGFR TKIs provides a basis for the
identification of predictive, mechanism-based biomarkers
and for the design of rational combination strategies. EGFR
activation occurs through ligand binding to receptor
monomers, which promotes dimer formation and enhanced
catalytic activity. Ligands for EGFR include EGF and
transforming growth factor α (TGFα) EGFR can form
EGFR-EGFR homodimers as well as heterodimers with
other members of the ErbB receptor family (ErbB2/HER2,
ErbB3/HER3, ErbB4/HER4) [15–17]. Within this family,
EGFR and ErbB4 have functional ligand binding and
catalytic domains. There are no known ligands for ErbB2
and its kinase activity is primarily transactivated by
dimerization with other ErbB family members [18]. In
contrast, ErbB3 lacks a functional kinase domain, but does
have a competent ligand-binding domain [19, 20], which
binds ligands of the neuregulin family. Although ErbB3
lacks enzymatic activity, it contains several tyrosine residues
within the YXXM motif, which can by phosphorylated by
heterodimer partners and by crosstalk with other receptors.
When phosphorylated, these YXXM sites serve as docking
sites for SH2-containing intracellular signaling proteins
including the p85 regulatory subunit of phosphatidyl
inositide-3 kinase (PI3K) [21–24]. Thus, ErbB3 is capable
of transducing intracellular signals despite its inherent lack of
kinase activity.
Different ErbB family dimers show distinct signaling
patterns. For example, EGFR-ErbB2 and EGFR-ErbB3
heterodimers are generally more effective than EGFR
homodimers at transducing growth and survival signals
[25]. Recent studies have shown that EGFR homodimers
may contribute primarily to activation of the MAPK
pathway, whereas EGFR-ErbB3 heterodimers preferentially
contribute to activation of the PI3K-AKT pathway (Fig. 1).
Small-interfering RNAs (siRNA) directed toward ErbB3
decrease AKT signaling, but not MAPK signaling [26].
Interestingly, ErbB3 expression and thus AKT activation is
associated with sensitivity to EGFR TKIs, suggesting that
ErbB3 and/or phospho-AKT could serve as positive
predictive biomarkers for EGFR TKIs.
EGFR mutations
Mutations within EGFR (exon 19 deletions, exon 20
insertions or point mutations that result in the L858R
substitution) give rise to enhanced catalytic activity, which
confers greater “addiction” of tumor cells to the EGFR
signaling pathway [27–30]. Tumor cells that harbor such
mutations are more sensitive to EGFR TKIs [31–33]. This
increased sensitivity to TKIs may be mediated by multiple
mechanisms, including “onco-addiction” to the EGFR
pathway and/or structural changes in EGFR that result in
higher binding affinities for TKIs. Indeed, the binding
affinity of EGFR TKIs is increased by greater than 10-fold
by the L858R substitution in EGFR [34]. Additionally, the
affinity for ATP, which competes for TKI binding, is
reduced by the L858 substitution, yielding an approximately
500-fold increase in the Kd (TKI) to Km (ATP) ratio.
Recently, secondary mutations in EGFR that result in a
T790M substitution have been shown to contribute to
acquired resistance to EGFR TKIs [35–39]. When NSCLC
cell lines expressing highly sensitive EGFR variants,
described above, were subjected to long term exposure to
gefitinib in vitro, the resulting resistance to gefitinib was
accompanied by the acquisition of secondary mutations in
EGFR that encode the T790M substitution [35]. This
observation has been validated in the clinic; patients whose
tumors harbor activating mutations of EGFR initially
respond well to EGFR TKIs, but their cancers eventually
progress. The development of resistance to EGFR TKIs in
approximately 50% of these patients is associated with the
acquisition secondary mutations that result in the T790M
substitution in EGFR [35, 36, 40, 41]. Residue 790 of
EGFR lies within the hinge region of the catalytic domain
and is the “gatekeeper” residue for EGFR. Interestingly,
“gatekeeper” mutations are commonly associated with
resistance to TKIs, such as the T315I mutation in BCR-
ABL that can confer resistance to imatinib in chronic
HER1 HER1 HER1 ErbB3
MAPK AKT
Fig. 1 Proposed model for signaling pathways mediated by EGFR
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myelogenous leukemia (CML) patients [42, 43]. Initial
studies suggested that EGFR TKIs may exhibit weaker
binding to the EGFR double mutants compared to either
wild-type (WT) EGFR or the single mutants (L858R or
exon 19/20 mutations). However, recent reports have
shown a three- to four-fold increase in TKI binding affinity
for the T790M-L858R double mutant compared to WT
EGFR. Despite this observation, the affinity of TKIs for the
single L858R mutant-EGFR was still approximately four-
fold greater [34]. Rather than being mediated by reduced
binding affinity, the reduced potency of EGFR TKIs for
T790M double mutants is driven by an associated increase
in the Km for ATP, which competes with the EGFR TKI for
binding in the catalytic domain.
In human tumors, T790M EGFR has been detected only
in cis with either of the two primary activating mutations
[35]. Although initial reports showed that the T790M
substitution, in an otherwise WT EGFR background,
conferred decreased sensitivity to reversible EGFR TKIs
such as gefitinib and erlotinib by 100-fold, the T790M
substitution has not been detected in the absence of either
of the two primary activating mutations either in established
tumor cell lines or in patient samples. Recently, character-
ization of the relative catalytic gain conferred by various
mutations, either alone or in combination has shed light
onto these observations [44]. Unlike the primary mutations
that confer a strong gain in catalytic activity compared to
WT EGFR, the T790M substitution results in only a modest
gain in catalytic activity compared to WT EGFR and is
relatively silent in the context of cellular signaling [44].
However, in combination with either of the two primary
activating mutations, T790M confers a synergistic gain in
catalytic activity. The development of acquired resistance
by the T790M substitution may be modeled in two ways. In
one model, the T790M substitution is absent in the initial
tumor cell population and arises de novo in one or more
clonal populations upon treatment with an EGFR TKI. In
the second model, the T790M substitution pre-exists in cis
with a primary activating mutation in a small population
and is subjected to positive selection pressure in the
presence of an EGFR TKI. Recent data suggest that the
latter scenario may be more likely because mutations
encoding T790M have been detected in cis with a primary
activating mutation in tumors from patients who had not
been treated with an EGFR TKI. The observation that this
mutation confers a gain in catalytic activity provides a
rationale for its co-existence in tumors with activating
mutations in EGFR but not in those tumors with WT EGFR
[45]. Given that the T790M substitution alone does not
confer substantially higher catalytic activity compared to
WT EGFR, it is unlikely that it would have a selective
advantage in a primary tumor. Collectively, these data
suggest a role for the T790M mutation for tumors that
harbor primary activating mutations in EGFR, but suggest
that this mode of resistance is unlikely among tumors of
WT EGFR status. Therefore, it is critically important that
we continue to study other mechanisms of resistance to
EGFR TKIs so that we can provide tailored treatment
regimens to appropriately defined patient subpopulations.
K-RAS mutations
Activating mutations in the gene encoding K-RAS in human
tumors have been implicated in reduced sensitivity to EGFR
inhibitors. The mechanistic rationale for this hypothesis is
based upon long-standing dogma: since K-RAS mainly
functions downstream of EGFR, then EGFR inhibitors should
have little impact on signaling through the RAS-RAF-MEK-
MAPK pathway [46]. In colorectal cancer patients, K-RAS
mutations are predictive for poor response to the EGFR
neutralizing antibodies, cetuximab or panitumumab [47, 48].
Currently, there are no definitive clinical data that extend this
finding to EGFR TKIs. In preclinical models K-RAS status is
not strongly associated with either sensitivity or insensitivity
to EGFR TKIs, but it will be important to carefully study
emerging clinical data [26, 49, 50].There are interesting
differences between the pharmacological mechanisms of
anti-EGFR MAbs and EGFR TKIs. In some preclinical
models, EGFR TKIs such as erlotinib inhibited both the
MAPK and AKT pathways, whereas the EGFR neutralizing
antibody, C225, affected only MAPK signaling [51]. This
distinction was associated with differential regulation of
EGFR homodimers and EGFR-ErbB3 heterodimers; while
both erlotinib and C225 similarly inhibited EGFR phosphor-
ylation, only erlotinib inhibited EGFR trans-phosphorylation
of ErbB3. This is consistent with the observation that C225
was unable to block PI3K-AKT signaling. These data
indicate that anti-EGFR MAbs, which affect signaling
preferentially through the MAPK pathway, might be more
sensitive to activating K-RAS mutations compared to EGFR
TKIs, which provide an additional activity by inhibiting
signaling through the AKT survival pathway. While limited
clinical data do suggest that mutant K-RAS may behave as a
modifier of erlotinib efficacy in NSCLC patients, it does not
appear to be a key determinant of efficacy to the same extent
as it is for anti-EGFR MAbs in colorectal cancer [52].
Furthermore, erlotinib has proven efficacy in combination
with gemcitabine for treatment of patients with advanced
pancreatic cancer, a tumor type that has a very high
prevalence (80–95%) of activating K-RAS mutations [53].
The utility of K-RAS mutations as predictive biomarkers for
EGFR TKIs is additionally obscured by their mutual
exclusivity with EGFR activating mutations, their association
with smoking, and by being a general indicator of poor
prognosis [54–57]. Clearly, further studies are necessary to
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fully elucidate the role of K-RAS mutations in affecting
EGFR TKI sensitivity.
Epithelial mesenchymal transition
Recent studies have shown that biomarkers associated with
epithelial mesenchymal transition (EMT) can be used to
predict sensitivity to EGFR TKIs [49, 50, 58–60]. Carci-
nomas originate as epithelial cells and express characteristic
epithelial markers such as E-cadherin, which function in
homotypic cell-cell adhesion [61]. While these cells can
rapidly proliferate upon oncogenic transformation, their
epithelial phenotype hinders their ability to migrate from
the primary tumor site or to survive in an anchorage
independent manner. Intrinsic and extrinsic signals can
trigger tumor cells to undergo an epithelial-mesenchymal
transition, whereby tumor cells lose the expression of
epithelial proteins such as E-cadherin and gain mesenchymal
markers including vimentin. Tumor cells that have under-
gone EMT exhibit a number of phenotypic hallmarks
including decreased cell-cell adherence, increased motility,
increased invasiveness and anchorage independent survival.
Proteomic and gene expression profiling experiments
revealed differential expression of epithelial and mesenchymal
proteins in erlotinib-sensitive and erlotinib–insensitive tumor
cell lines [49, 50]. Those tumor cells most sensitive to growth
inhibition by erlotinib in vitro and in vivo expressed epithelial
protein markers such as E-cadherin and β-catenin. In
contrast, tumor cells that had undergone EMT were less
sensitive to erlotinib and accordingly downregulated the
expression of epithelial markers while increasing the expres-
sion of mesenchymal markers, including vimentin and
fibronectin. Erlotinib–sensitive tumor cell lines exhibited the
cobblestone appearance typical of epithelial cells, while
erlotinib–insensitive tumor cell lines exhibited a spindle-like
morphology that is typical of mesenchymal cells. These
preclinical observations have been substantiated with some
preliminary analyses from at least one clinical trial [50]. A
retrospective analysis of samples taken from the TRIBUTE
study, which evaluated the efficacy of carboplatin/paclitaxel
compared to carboplatin/paclitaxel plus erlotinib in front line
NSCLC, was conducted to investigate the possible correlation
of EMT status with erlotinib sensitivity. While the addition of
erlotinib to chemotherapy did not provide a statistically
significant benefit in terms of progression-free survival (PFS)
across the broad group of unselected patients, a retrospective
analysis showed that there was a significant relationship
between longer time to progression (hazard ratio=0.37) and
E-cadherin expression in patient tumors for the erlotinib plus
chemotherapy arm compared to the chemotherapy-alone arm.
Further preclinical studies have shown that EMT may
play a role in predicting sensitivity to EGFR inhibitors
across a number of tumor types including pancreatic,
colorectal, breast, bladder and hepatocellular cancers as
well as SCCHN [59, 60]. For example, in pancreatic cancer
cell lines, erlotinib inhibited EGFR phosphorylation in both
erlotinib–insensitive (mesenchymal) and erlotinib–sensitive
(epithelial) tumor cells, however, erlotinib only inhibited
AKT and MAPK signaling in epithelial cell lines (erlotinib
sensitive).
Recent studies into the mechanism by which erlotinib
sensitivity is restricted to epithelial tumor cells have shown
that ErbB3 expression, which mediates EGFR directed
AKT signaling, also appears to be restricted to epithelial
tumor cells, and expression of ErbB3 is decreased when
tumor cells undergo EMT. Snail, a transcription factor that
functions to promote EMT, represses transcription of CDH1
(the gene encoding E-cadherin) and ErbB3 [62]. In
experimental models where EMT can be induced in vitro
by treating tumor cells with TGFβ, increased expression of
mesenchymal proteins including snail, zeb1, and vimentin
is associated with decreased expression of both E-cadherin
and ErbB3 [63]. Thus, when tumor cells undergo EMT they
lose an important conduit for transducing EGFR-driven
signals to the AKT pathway.
EMT can also contribute to EGFR TKI resistance by
shifting the tumor cells’ predominant reliance on EGFR to
other networks, such as those activated by fibroblast growth
factor receptor (FGFR), platelet derived growth factor
receptor (PDGFR) or α5β1 integrin [63]. One hypothesis
posits that epithelial tumor cells may rely on one suite of
RTKs, including EGFR, for growth and survival in the
epithelial state and also to enable EMT, but once the
transition to the mesenchymal phenotype occurs, the tumor
cells rely on a different array of signaling inputs to drive
growth, survival, and virulence. There may be significant
flexibility built into this system such that tumor cells are
able to thrive in different metastatic microenvironments that
offer distinct sets of “drivers.” Indeed, Minn et al. have
shown distinct gene expression profiles from different
metastatic sites in breast cancers [64].
Redundant RTKs
EGFR and other RTKs including the IGF-1R, MET, ErbB2/
HER2, FGFR, and PDGFR can function redundantly or
cooperatively to activate downstream signal transduction
networks including the MAPK and AKT pathways.
Activation of these other pathways can provide alternative
proliferation and/or survival signals to bypass EGFR
blockade. Tumor cells may intrinsically use independent
RTKs de novo, where receptor crosstalk does not initially
occur, but where inhibition of each independent pathway is
required for maximal efficacy. Treatment with an EGFR
inhibitor might also actively promote the activation of other
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RTKs, thereby initiating receptor crosstalk. By broadening our
knowledge of specific RTKs that can contribute to insensitiv-
ity or acquired resistance to EGFR inhibitors, we will be better
prepared to design rational combination regimens to maxi-
mize patient benefit. Below, we will summarize preclinical
data supporting a role of IGF-1R and MET in contributing
to intrinsic insensitivity or acquired resistance to EGFR
inhibitors.
Although IGF-1R expression has not been associated
with intrinsic resistance to the EGFR inhibitor gefitinib in
patients with advanced non-small cell lung cancer [65], the
phosphorylation state of IGF-1R (p-IGF-1R) was increased
upon treatment with gefitinib. Resistance to EGFR inhib-
itors via p-IGF-1R has been reported for a number of tumor
models including glioblastoma [66], breast and prostate
[67], lung [68, 69], hepatocellular [70]), SCCHN [69], and
colorectal [71]. Several mechanisms for IGF-1R-mediated
acquired resistance to erlotinib have been described. One
mechanism involves the formation of activated EGFR/IGF-
1R complexes on the cell surface upon EGFR blockade.
This has been shown in NSCLC cell lines both in vitro and
in vivo upon erlotinib treatment, and this increase in EGFR/
IGF-1R complexes is thought to enable the coordinated
transmission of growth and survival signals to the AKT and
MAPK pathways, such that targeted inhibition of both
EGFR and IGF-1R is required for maximal efficacy (Fig. 2)
[68]. Guix et al. reported that the interaction between IGF-
1R and IRS-1, and thus active signaling to AKT, was
induced upon treatment with erlotinib [69]). Increased
formation of EGFR/IGF-1R complexes is thought to lead
to further increases in the expression of EGFR and of the
anti-apoptotic protein survivin in an mTOR-mediated
manner. Blocking the IGF-1R pathway is sufficient to
suppress survivin protein expression and to restore pro-
apoptotic activities of erlotinib in NSCLC cells both in vitro
and in vivo [68]. Furthermore, knockdown of survivin
expression by siRNA resulted in increased sensitivity to
erlotinib for NSCLC tumor cells, underscoring the critical
role of survivin as a mechanism for IGF-1R mediated
acquired resistance to erlotinib.
Crosstalk between EGFR and IGF-1R has been reported in
pancreatic, colorectal and NSCLC cell lines [71]. Blockade of
IGF-1R or EGFR by pharmacological approaches (e.g., the
low molecular weight IGF-1R inhibitor PQIP, erlotinib) or
by molecular approaches (e.g., siRNA) resulted in compen-
satory activation of the reciprocal receptor. Only the
combined blockade of EGFR and IGF-1R resulted in
sustained inhibition of the AKT pathway. Phenotypically,
combined blockade of these receptors caused a synergistic
inhibition of cell growth and survival in vitro and resulted in
greater decreases in xenograft tumor growth compared to
inhibition of either target alone. In fact, in a number of
pancreatic, NSCLC and colon xenograft models in which
either erlotinib or PQIP caused reduction of tumor growth
rates or stasis, the combination of erlotinib plus PQIP caused
bona fide and durable tumor regressions. Inhibition of the
MAPK pathway by erlotinib resulted in increased IGF-1R-
IRS-1 signaling through AKT, opening up an opportunity for
PQIP to shut down this important escape mechanism.
Some IGF binding proteins (IGFBPs) can attenuate IGF-
1r activation by acting as “chelators” of its ligands, IGF-1
and IGF-2. Therefore, an additional mechanism that may
contribute to IGF-1R-mediated EGFR TKI resistance
involves decreased expression of IGF-binding proteins,
particularly IGFBP3 and IGFBP4 [69]). In a gefitinib-
resistant variant of the A431 epidermoid carcinoma cell
line, derived by long term gefitinib exposure, gefitinib
retained the ability to inhibit phosphorylation of EGFR,
ErbB3, and MAPK. However, gefitinib lost the ability to
inhibit AKT phosphorylation, and this was associated with
increased phospho-IGF-1R. The gefitinib resistant A431
variant exhibited increased complex formation between
IRS-1 and PI3K, suggesting that resistance may be
mediated by enhanced activity of IGF-1R/IRS-1/PI3K
signaling. Gene expression profiling revealed that mRNAs
encoding IGFBP3 and IGFBP4 were downregulated in the
resistant clones. Addition of exogenous IGFBP3 to gefitinib–
resistant A431 cultures restored sensitivity to gefitinib,
further implicating IGF-1R signaling as the resistance
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combination of EGFR and IGF-1R inhibitors, gefitinib and a
neutralizing antibody to IGF-1R, did not develop resistance
to single agent gefitinib. Collectively, these data highlight the
importance of IGF-1R activation as a mechanism to escape
EGFR inhibition and suggest that the combined blockade of
EGFR and IGF-1R might provide substantial benefit for
many cancer patients.
Earlier, we summarized data showing that EGFR-ErbB3
heterodimers are potent activators of the AKT pathway in a
subset of NSCLC cell lines and that ErbB3 in the context of
EGFR expression may be a good predictor of sensitivity to
EGFR TKIs [72]. In addition to EGFR, other RTKs such as
MET also signal through ErbB3 to activate the AKT
pathway, providing a resistance mechanism to EGFR
inhibitors (Fig. 3) [73]. MET is receptor for hepatocyte
growth factor (HGF), which is known to activate multiple
signal transduction pathways including the AKT pathway
[74–76]. Genomic amplification of MET results in in-
creased expression of the MET protein, increased phos-
phorylation of ErbB3 and activation of PI3K/AKT in an
EGFR- and ErB2-independent manner [73]. Furthermore,
MET amplification has been detected in lung tumors with
EGFR mutations that confer resistance to gefitinib or
erlotinib [41, 73]. In one study, MET amplification occurred
during the generation of gefitinib–resistant NSCLC by
prolonged treatment with gefitinib. Increased phosphoryla-
tion of MET, ErbB3, EGFR and AKT accompanied MET
amplification and the acquisition of gefitinib–resistance.
While neither gefitinib nor the MET inhibitor, PHA-
665752, were effective as single agents in this model, the
combination of the two agents inhibited both ErbB3 and
AKT phosphorylation and decreased tumor cell proliferation
and survival and promoted apoptosis. Furthermore, down-
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restored gefitinib sensitivity. Coversely, ectopic overexpres-
sion of MET in the parental cells conferred gefitinb
resistance. MET amplification as a resistance mechanism to
EGFR inhibitors has also been observed in the clinic. In a
group of 18 NSCLC patients whose cancers initially
responded to EGFR TKI treatment, disease progression was
associated with MET amplification for 22% of the patients (4
out of 18). Together, these observations support the concept
that concomitant inhibition of both EGFR and MET might
be required to maximize efficacy against cancers predisposed
to employ MET amplification as a means of circumventing
EGFR blockade. Identifying patients whose tumors might be
predisposed to this mode of EGFR TKI resistance is a key
challenge to translational researchers.
Figure 3.
Conclusions
Since their approval, EGFR TKIs have provided tremen-
dous benefit to large numbers of cancer patients. However,
we continue to face important challenges such as identify-
ing patients a prior who are most likely to benefit from
these drugs, and delaying or preventing drug-resistance.
Preclinical studies have provided a platform for identifying
predictive biomarkers and for broadening our understand-
ing of mechanisms of resistance to EGFR-targeted drugs
(Fig. 4). Specific activating mutations in EGFR are
associated with enhanced sensitivity to EGFR TKIs. While
patients with tumors harboring these activated mutant forms
of EGFR initially respond well to EGFR TKIs, long term
treatment can result in resistance, mediated in part by the
acquisition of a secondary point mutation, T790M, within
EGFR. However, preclinical data suggest that the T790M
mode of resistance is unlikely to predominate for tumors of
WT EGFR status.
Inhibition of both MAPK and AKT signaling is an
important determinant of erlotinib sensitivity in NSCLC
and pancreatic cancer models. Activating K-RAS mutations
are believed by some to confer resistance to EGFR
inhibitors activating the MAPK pathway downstream of
EGFR. Indeed, patients with colorectal cancers harboring
K-RAS mutations appear to respond poorly to anti-EGFR
MAbs [47, 77]. Currently, data for the predictive value of
K-RAS mutations as measure of response to EGFR TKIs is
less clear. However, observations for select tumor cells
where EGFR antibodies affect signaling primarily through
the MAPK pathway, while EGFR TKIs can affect signaling
through both the MAPK and the AKT pathway, may
indicate that TKIs could be less affected by K-RAS
mutations.
ErbB3 has emerged as a primary conduit for EGFR-
directed AKT signaling and determinant of erlotinib
sensitivity in preclinical models. ErbB3 is expressed primar-
ily by epithelial-like cancer cells but not those that have
undergone EMT. Thus, there is an emerging mechanistic link
between ErbB3 and EMT with respect to understanding
sensitivity and resistance to EGFR inhibitors. Furthermore,
the observation that ErbB3-AKT signaling is blocked by
EGFR TKIs but not by anti-EGFR MAbs further substan-
tiates the notion that all EGFR inhibitors are not identical in
terms of their spectra of activity against human cancers.
Distinct sets of predictive biomarkers should be pursued for
anti-EGFR MAbs and EGFR TKIs.
Complementary signaling and RTK reciprocity is an
emerging concept in the context of EGFR TKIs. It is clear
that EGFR and IGF-1R functionally interact in terms of
ERK and AKT signaling and that combined blockade of
EGFR and IGF-1R may be an effective strategy to treat a
wide range of cancer and to prevent or delay the acquisition
of resistance to EGFR inhibitors [68–70]. MET can also
compensate for EGFR-resistance inhibition to maintain
ErbB3-PI3K-AKT signaling. The combination of EGFR
inhibitors and MET inhibitors promote sustained tumor
growth inhibition in preclinical models. Collectively, these
observations suggest that combinations of molecularly
targeted drugs in molecularly-specified patient populations
will be required for maximal efficacy.
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